RecruitingPhase 1NCT06209359

Mechanisms of Diuretic Resistance in Heart Failure, Aim 3


Sponsor

Yale University

Enrollment

50 participants

Start Date

Jul 24, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Randomized double-blind placebo-controlled crossover study design


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study examines why some patients with heart failure become resistant to diuretics (water pills used to remove excess fluid), and whether certain kidney or cardiovascular tests can predict or explain this. Participants will have measurements taken to understand the mechanisms behind diuretic resistance. **You may be eligible if...** - You have a clinical diagnosis of heart failure - You have shown resistance to diuretics (your kidneys do not excrete enough sodium in response to a standard dose) - Your heart failure medications are stable and you have not been hospitalized urgently in the last 2 months - Your blood potassium, sodium, and hemoglobin levels are within acceptable ranges **You may NOT be eligible if...** - Your heart failure medications are being changed during the study period - You have had a recent emergency hospitalization related to heart failure - Your lab values are outside the safe range for participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAmmonium Chloride

Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.

DRUGPlacebo

Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.


Locations(1)

Yale University

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06209359


Related Trials